Curanex Pharmaceuticals Inc 8-K

What Happened
In an 8-K filed May 7, 2026, Curanex Pharmaceuticals Inc (CURX) reported that Nasdaq notified the company it remained out of compliance with the $1.00 minimum closing bid-price requirement. Nasdaq originally sent a notice on November 5, 2025 and gave a 180-day cure period ending May 4, 2026. On May 5, 2026 Nasdaq granted Curanex an additional 180-calendar-day compliance period, extending the deadline to November 2, 2026, because the company otherwise meets Nasdaq’s initial listing requirements (except for the bid price). The company has told Nasdaq it may cure the deficiency during the second period, including by implementing a reverse stock split if necessary.

Key Details

• Nasdaq initial notice: November 5, 2025; first 180-day cure period expired May 4, 2026.
• Additional cure period granted on May 5, 2026, extending the deadline to November 2, 2026 (another 180 days).
• Minimum requirement to regain compliance: closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days.
• If not compliant by Nov 2, 2026, Nasdaq will notify the company of delisting; Curanex may appeal to a Nasdaq Hearings Panel. Company may pursue a reverse stock split to meet the requirement.

Why It Matters
This notice signals a risk to the company’s continued Nasdaq listing if the stock price remains below $1.00. Delisting could reduce liquidity and visibility for shareholders and may affect institutional ownership. A reverse stock split is a common remedy that can raise the per-share price but reduces the number of outstanding shares proportionally. The company has time through November 2, 2026 to regain compliance, but the filing makes clear there is no assurance it will succeed.